Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SPP1 |
| Gene Name: | SPP1 |
| Protein Full Name: | Osteopontin |
| Alias: | BNSP; Bone sialoprotein 1; BSPI; Early T-lymphocyte activation 1; ETA-1; Nephropontin; OPN; OSTP; Secreted phosphoprotein 1; SPP-1; Urinary stone protein; Uropontin |
| Mass (Da): | 35423 |
| Number AA: | 314 |
| UniProt ID: | P10451 |
| Locus ID: | 6696 |
| COSMIC ID: | SPP1 |
| Gene location on chromosome: | 4q22.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19685 |
| Percent of cancer specimens with mutations: | 0.31 |
| Normal role description: | Secreted protein. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction. Acts as a cytokine involved in enhancing production of interferon-gamma and interleukin-12 and reducing production of interleukin-10 and is essential in the pathway that leads to type I immunity. Altered expression levels associated with adhesion, migration, invasion, enhanced tumour survival, tumour angiogenesis, and metastasis and it was suggested to be be an effector of activated oncogenes. |